98 related articles for article (PubMed ID: 12126315)
1. Digging for data from the COX-2 trials.
McCormack JP; Rangno R
CMAJ; 2002 Jun; 166(13):1649-50. PubMed ID: 12126315
[No Abstract] [Full Text] [Related]
2. Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
Geis GS
BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134853
[No Abstract] [Full Text] [Related]
3. Celecoxib and the CLASS trial: data massaging by industry.
Prescrire Int; 2002 Dec; 11(62):190-1. PubMed ID: 12472103
[No Abstract] [Full Text] [Related]
4. Drug testing. Massive trial of Celebrex seeks to settle safety concerns.
Couzin J
Science; 2005 Dec; 310(5756):1890-1. PubMed ID: 16373546
[No Abstract] [Full Text] [Related]
5. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
[No Abstract] [Full Text] [Related]
6. [Mobility and quality of life for arthrosis and rheumatism patients. Modern pain management with selective cox-2 inhibition].
MMW Fortschr Med; 2002 Jul; 144(29-30):52. PubMed ID: 12219613
[No Abstract] [Full Text] [Related]
7. [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
MMW Fortschr Med; 2003 May; 145(18):54. PubMed ID: 12808824
[No Abstract] [Full Text] [Related]
8. COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?
Bannwarth B
Expert Opin Drug Saf; 2006 Jan; 5(1):1-2; author reply 1-2. PubMed ID: 16370948
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis.
Suárez-Otero R; Robles-San Román M; Jaimes-Hernández J; Oropeza-De La Madrid E; Medina-Peñaloza RM; Rosas-Ramos R; Castañeda-Hernández G
Proc West Pharmacol Soc; 2002; 45():26-8. PubMed ID: 12434517
[No Abstract] [Full Text] [Related]
10. [Rapid, strong and long-term effectiveness. Coxib also effective in toothache].
MMW Fortschr Med; 2003 Jan; 145(1-2):53. PubMed ID: 12638443
[No Abstract] [Full Text] [Related]
11. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
Pavelka K; Recker DP; Verburg KM
Rheumatology (Oxford); 2003 Oct; 42(10):1207-15. PubMed ID: 12810937
[TBL] [Abstract][Full Text] [Related]
12. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
[TBL] [Abstract][Full Text] [Related]
13. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
Hawk E; Viner JL
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
[No Abstract] [Full Text] [Related]
14. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
[No Abstract] [Full Text] [Related]
15. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials. Nail-biting time for trials of COX-2 drugs.
Couzin J
Science; 2004 Dec; 306(5702):1673-5. PubMed ID: 15576585
[No Abstract] [Full Text] [Related]
17. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
[TBL] [Abstract][Full Text] [Related]
18. Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS.
Prescrire Int; 2003 Jun; 12(65):89-90. PubMed ID: 12825570
[TBL] [Abstract][Full Text] [Related]
19. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
20. [Celecoxib and the CLASS study--worse and worse...].
Slørdal L
Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2219. PubMed ID: 12426903
[No Abstract] [Full Text] [Related]
[Next] [New Search]
